Breaking News Instant updates and real-time market news.

ALBO

Albireo Pharma

$31.63

-0.72 (-2.23%)

07:45
08/07/18
08/07
07:45
08/07/18
07:45

Albireo Pharma reports Q2 EPS ($1.22), consensus (95c)

Reports Q2 revenue $730,000, consensus $570,000.

  • 07

    Aug

  • 14

    Aug

  • 30

    Aug

  • 31

    Aug

ALBO Albireo Pharma
$31.63

-0.72 (-2.23%)

11/15/17
11/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Albireo Pharma (ALBO) initiated with a Buy at Roth Capital. 2. Qudian (QD) was initiated with a Buy at Stifel and an Equal Weight at Morgan Stanley. 3. Platform Specialty Products (PAH) reinitiated with a Neutral at Credit Suisse. 4. Karyopharm (KPTI) assumed with a Buy at H.C. Wainwright. 5. Extraction Oil & Gas (XOG) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
NEED
02/02/18
NO CHANGE
Target $50
NEED
Buy
Albireo Pharma price target raised to $50 from $35 at Needham
Needham analyst Alan Carr raised his price target on Albireo Pharma to $50 and kept his Buy rating, revising his model to reflect the new elobixibat royalty agreement and subsequent regulatory approval of the drug in Japan for Chronic Constipation. The analyst adds he is "favorably inclined" toward results expected to be released around 2019-end based on the Phase 2 data of the drug.
04/20/18
JEFF
04/20/18
INITIATION
Target $50
JEFF
Buy
Albireo Pharma initiated with a Buy at Jefferies
Jefferies analyst Eun Yang starts Albireo Pharma with a Buy rating and $50 price target. The company is a "relatively under-recognized story," but has an attractive Phase 3 pediatric orphan liver disease product, designed to address a real unmet need, Yang tells investors in a research note. She thinks appreciation in the shares is likely ahead of the Phase 3 lead product data towards the end of 2019.
04/20/18
04/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Roku (ROKU) initiated with a Hold at Loop Capital. 2. Merit Medical (MMSI) initiated with a Buy at Needham. 3. Wingstop (WING) initiated with a Buy at BTIG. 4. Globant (GLOB) initiated with a Hold at HSBC. 5. Albireo Pharma (ALBO) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.